Publications
Download CSV
Download XLSX
Download TXT
Tables
2024 (855)
2023 (887)
2022 (831)
2021 (892)
2020 (640)
2019 (727)
2018 (651)
2017 (681)
2016 (664)
2015 (429)
2014 (376)
2013 (319)
2012 (245)
2011 (163)
2010 (139)
2000 (2)
1977 (2)
All (8503)
Infrastructure Units
Infrastructure Units list
Infrastructure Units table
Researchers
Subset
Documentation
About
Contact
Software
Login
Bexell D
JSON
CSV
XLSX
TXT
Family name
Bexell
Given name
Daniel
Initials
D
ORCID
ORCID
0000-0001-9426-9550
Affiliations
Department of Laboratory Medicine, Translational Cancer Research, Lund University Cancer Center, Lund University, Lund, Sweden.
6 publications
PubMed
DOI
Crossref
Early evolutionary branching across spatial domains predisposes to clonal replacement under chemotherapy in neuroblastoma.
Karlsson J
, Yasui H,
Mañas A
, ...,
Bexell D
,
Gisselsson D
Nat Commun
15
(1) 8992 [2024-10-18; online 2024-10-18]
Clinical Genomics Lund [Service]
PubMed
DOI
Crossref
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance.
Mañas A
,
Aaltonen K
,
Andersson N
, ..., Gisselsson D,
Bexell D
Sci Adv
8
(43) eabq4617 [2022-10-28; online 2022-10-28]
Clinical Genomics Lund [Service]
PubMed
DOI
Crossref
Engineering human mini-bones for the standardized modeling of healthy hematopoiesis, leukemia, and solid tumor metastasis.
Grigoryan A
,
Zacharaki D
,
Balhuizen A
, ...,
Bexell D
,
Bourgine PE
Sci Transl Med
14
(666) eabm6391 [2022-10-12; online 2022-10-12]
Clinical Genomics Lund [Service]
PubMed
DOI
Crossref
Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma.
Hansson K
,
Radke K
,
Aaltonen K
, ..., Gisselsson D,
Bexell D
Sci Transl Med
12
(562) - [2020-09-23; online 2020-09-25]
Clinical Genomics Lund [Service]
PubMed
DOI
Crossref
Integrative discovery of treatments for high-risk neuroblastoma.
Almstedt E
,
Elgendy R
, Hekmati N, ..., Krona C, Nelander S
Nat Commun
11
(1) 71 [2020-01-03; online 2020-01-03]
Genome Engineering Zebrafish [Service]
PubMed
DOI
Crossref
Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
Mohlin S
, Hansson K, Radke K, ..., von Stedingk K,
Bexell D
EMBO Mol Med
11
(8) e10058 [2019-08-00; online 2019-07-16]
NGI Uppsala (Uppsala Genome Center) [Service]
National Genomics Infrastructure [Service]
Structural Proteomics [Service]
SciLifeLab Data Centre
Publications
9.5.1